These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34893157)

  • 1. A molecular genetics view on Mucopolysaccharidosis Type II.
    Verma S; Pantoom S; Petters J; Pandey AK; Hermann A; Lukas J
    Mutat Res Rev Mutat Res; 2021; 788():108392. PubMed ID: 34893157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.
    Kosuga M; Mashima R; Hirakiyama A; Fuji N; Kumagai T; Seo JH; Nikaido M; Saito S; Ohno K; Sakuraba H; Okuyama T
    Mol Genet Metab; 2016 Jul; 118(3):190-197. PubMed ID: 27246110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients.
    Chkioua L; Grissa O; Leban N; Gribaa M; Boudabous H; Turkia HB; Ferchichi S; Tebib N; Laradi S
    BMC Med Genet; 2020 May; 21(1):111. PubMed ID: 32448126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype.
    Vollebregt AAM; Hoogeveen-Westerveld M; Kroos MA; Oussoren E; Plug I; Ruijter GJ; van der Ploeg AT; Pijnappel WWMP
    Dev Med Child Neurol; 2017 Oct; 59(10):1063-1070. PubMed ID: 28543354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
    Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
    Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosing lysosomal storage disorders: mucopolysaccharidosis type II.
    Johnson BA; van Diggelen OP; Dajnoki A; Bodamer OA
    Curr Protoc Hum Genet; 2013 Oct; 79():17.14.1-17.14.9. PubMed ID: 24510650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
    Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
    Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers.
    Lin SP; Chang JH; Lee-Chen GJ; Lin DS; Lin HY; Chuang CK
    Clin Chim Acta; 2006 Jul; 369(1):29-34. PubMed ID: 16480701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Functional Characterization of
    Lin HY; Tu RY; Chern SR; Lo YT; Fran S; Wei FJ; Huang SF; Tsai SY; Chang YH; Lee CL; Lin SP; Chuang CK
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.
    Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W
    Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
    Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis of Mucopolysaccharidosis Type II and Construction of a Database of Mutant Iduronate 2-Sulfatases.
    Saito S; Ohno K; Okuyama T; Sakuraba H
    PLoS One; 2016; 11(10):e0163964. PubMed ID: 27695081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-phenotype studies in a large cohort of Brazilian patients with Hunter syndrome.
    Josahkian JA; Brusius-Facchin AC; Netto ABO; Leistner-Segal S; Málaga DR; Burin MG; Michelin-Tirelli K; Trapp FB; Cardoso-Dos-Santos AC; Ribeiro EM; Kim CA; de Siqueira ACM; Santos ML; do Valle DA; da Silva RTB; Horovitz DDG; de Medeiros PFV; de Souza CFM; Giuliani LR; Miguel DSCG; Santana-da-Silva LC; Galera MF; Giugliani R
    Am J Med Genet C Semin Med Genet; 2021 Sep; 187(3):349-356. PubMed ID: 33960103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts.
    Friso A; Tomanin R; Alba S; Gasparotto N; Puicher EP; Fusco M; Hortelano G; Muenzer J; Marin O; Zacchello F; Scarpa M
    J Gene Med; 2005 Nov; 7(11):1482-91. PubMed ID: 15966019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and genotypes of 201 patients with mucopolysaccharidosis type II in China: A retrospective, observational study.
    Zhong L; Gao X; Wang Y; Qiu W; Han L; Gu X; Zhang H
    Clin Genet; 2023 Jun; 103(6):655-662. PubMed ID: 36945845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and structure characterization of novel IDS variants causing mucopolysaccharidosis type II: A retrospective analysis of 30 Chinese children.
    Zhao XY; Qiao GM; Liu F
    Clin Chim Acta; 2021 Dec; 523():386-394. PubMed ID: 34670126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.